Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 2/2018

01-02-2018 | Review Article

The potential roles of bacteria to improve radiation treatment outcome

Authors: E. Kouhsari, A. Ghadimi-Daresajini, H. Abdollahi, N. Amirmozafari, S. R. Mahdavi, S. Abbasian, S. H. Mousavi, H. F. Yaseri, M. Moghaderi

Published in: Clinical and Translational Oncology | Issue 2/2018

Login to get access

Abstract

Many combined therapies have been proposed to enhance radiotherapy outcome, but they have several limitations. As a new feasible strategy, combination of radiotherapy with bacteria showed a significant positive impact on the tumor treatment and metastasis inhibition. Although probiotic bacteria and radiotherapy alone can be effective in the treatment of different cancers, the combination of these two therapies seems to enhance therapeutic outcome and is cost-effective. Bacterial cells can act as therapeutic/gene/drug delivery vehicles as well as theranostic agents. In this communication, we reviewed current evidences, studies, suggestions, and future-based directions on combination of radiotherapy and bacteria. In another sections, an overview on tumor hypoxia, bacteria in cancer therapy, and combination of radiotherapy and bacteria is presented. A brief overview on trials and animal studies which used bacteria to protect normal tissues against radiotherapy-induced complications is also included.
Literature
1.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed
2.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMed
3.
Bentzen SM, Heeren G, Cottier B, Slotman B, Glimelius B, Lievens Y, et al. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol. 2005;75(3):355–65.CrossRefPubMed
4.
Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. Sci Tansl Med. 2013;5(173):1732sr2-sr2.
5.
Datta N, Ordóñez SG, Gaipl U, Paulides M, Crezee H, Gellermann J, et al. Local hyperthermia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future. Cancer Treat Rev. 2015;41(9):742–53.CrossRefPubMed
6.
Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol. 2004;49(18):N309.CrossRefPubMed
7.
Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 2002;296(5577):2404–7.CrossRefPubMed
8.
Higgins GS, O’Cathail SM, Muschel RJ, McKenna WG. Drug radiotherapy combinations: review of previous failures and reasons for future optimism. Cancer Treat Rev. 2015;41(2):105–13.CrossRefPubMed
9.
Winczura P, Jassem J. Combined treatment with cytoprotective agents and radiotherapy. Cancer Treat Rev. 2010;36(3):268–75.CrossRefPubMed
10.
Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):256–65.
11.
Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11(4):239–53.CrossRefPubMed
12.
Richardson RB, Harper M-E. Mitochondrial stress controls the radiosensitivity of the oxygen effect: implications for radiotherapy. Oncotarget. 2016;7(16):21469.CrossRefPubMedPubMedCentral
13.
Hill RP, Bristow RG, Fyles A, Koritzinsky M, Milosevic M, Wouters BG. Hypoxia and predicting radiation response. Semin Radiat Oncol. 2015;25(4):260–72.CrossRefPubMed
14.
Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M, Noman MZ. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol. 2012;3:21.CrossRefPubMedPubMedCentral
15.
Wang W-M, Zhao Z-L, Ma S-R, Yu G-T, Liu B, Zhang L, et al. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and notch1 in head neck squamous cell carcinoma. PLoS One. 2015;10(2):e0119723.CrossRefPubMedPubMedCentral
16.
17.
18.
Feng H, Wang J, Chen W, Shan B, Guo Y, Xu J, et al. Hypoxia-induced autophagy as an additional mechanism in human osteosarcoma radioresistance. J Bone Oncol. 2016;5(2):67–73.CrossRefPubMedPubMedCentral
19.
Corry J, Rischin D. Strategies to overcome accelerated repopulation and hypoxia—What have we learned from clinical trials? Semin Oncol. 2004;31(6):802–8.CrossRefPubMed
20.
Peters LJ. Targeting hypoxia in head and neck cancer. Act Oncol. 2001;40(8):937–40.CrossRef
21.
Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 2007;26(2):241–8.CrossRefPubMed
22.
Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 1996;6(1):10–21.CrossRefPubMed
23.
Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med. 2009;9(4):442–58.CrossRefPubMedPubMedCentral
24.
Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, Stripp DC, et al. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Int J Radiat Oncol Biol Phys. 2007;69(4):1008–17.CrossRefPubMed
25.
Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys. 2005;63(1):25–36.CrossRefPubMed
26.
Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol. 2007;19(6):397–417.CrossRef
27.
Denny WA, Wilson WR. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Exp Opin Invest Drugs. 2000;9(12):2889–901.CrossRef
28.
Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer. 2009;9(2):134–42.CrossRefPubMedPubMedCentral
29.
Rodemann HP, Blaese MA. Responses of normal cells to ionizing radiation. Semin Radiat Oncol. 2007;17(2):81–8.CrossRefPubMed
30.
Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27(3):247–54.CrossRefPubMed
31.
32.
33.
Felgner S, Kocijancic D, Frahm M, Weiss S. Bacteria in cancer therapy: renaissance of an old concept. Int J Microbiol. 2016;8(45):17–28.
34.
Nallar SC, Xu D-Q, Kalvakolanu DV. Bacteria and genetically modified bacteria as cancer therapeutics: current advances and challenges. Cytokine. 2017;89:160–72.CrossRefPubMed
35.
36.
Carswell E, Old LJ, Kassel R, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Nat Acad Sci. 1975;72(9):3666–70.CrossRefPubMedPubMedCentral
37.
Nougayrède J-P, Taieb F, De Rycke J, Oswald E. Cyclomodulins: bacterial effectors that modulate the eukaryotic cell cycle. Trend Microbiol. 2005;13(3):103–10.CrossRef
38.
Oswald E, Sugai M, Labigne A, Wu HC, Fiorentini C, Boquet P, et al. Cytotoxic necrotizing factor type 2 produced by virulent Escherichia coli modifies the small GTP-binding proteins Rho involved in assembly of actin stress fibers. Proc Nat Acad Sci. 1994;91(9):3814–8.CrossRefPubMedPubMedCentral
39.
40.
41.
Wei MQ, Ellem KA, Dunn P, West MJ, Bai CX, Vogelstein B. Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. Eur J Cancer. 2007;43(3):490–6.CrossRefPubMed
42.
Ryan RM, Green J, Lewis CE. Use of bacteria in anti-cancer therapies. BioEssays. 2006;28(1):84–94.CrossRefPubMed
43.
Van Mellaert L, Barbé S, Anné J. Clostridium spores as anti-tumour agents. Trend Microbiol. 2006;14(4):190–6.CrossRef
44.
45.
Fensterle J, Bergmann B, Yone C, Hotz C, Meyer S, Spreng S, et al. Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B. Cancer Gene Ther. 2008;15(2):85–93.CrossRefPubMed
46.
Zhao M, Yang M, Ma H, Li X, Tan X, Li S, et al. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res. 2006;66(15):7647–52.CrossRefPubMed
47.
Avogadri F, Martinoli C, Petrovska L, Chiodoni C, Transidico P, Bronte V, et al. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res. 2005;65(9):3920–7.CrossRefPubMed
48.
Frankel AE, Rossi P, Kuzel TM, Foss F. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr Cancer Drug Targets. 2002;2(1):19–36.CrossRefPubMed
49.
Hagihara N, Walbridge S, Olson AW, Oldfield EH, Youle RJ. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res. 2000;60(2):230–4.PubMed
50.
Xu J, Liu XS, Zhou S-F, Wei MQ. Combination of immunotherapy with anaerobic bacteria for immunogene therapy of solid tumours. Gene Ther Mol Biol. 2009;13:36–52.
51.
Sznol M, Lin SL, Bermudes D, Zheng L-M, King I. Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest. 2000;105(8):1027–30.CrossRefPubMedPubMedCentral
52.
53.
Parvez S, Malik KA, Ah Kang S, Kim HY. Probiotics and their fermented food products are beneficial for health. J Appl Microbiol. 2006;100(6):1171–85.CrossRefPubMed
54.
Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr. 2001;73(2):451s–5s.PubMed
55.
Bettegowda C, Dang LH, Abrams R, Huso DL, Dillehay L, Cheong I, et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Nat Acad Sci. 2003;100(25):15083–8.CrossRefPubMedPubMedCentral
56.
Nuyts S, Van Mellaert L, Theys J, Landuyt W, Lambin P, Anné J. The use of radiation-induced bacterial promoters in anaerobic conditions: a means to control gene expression in clostridium-mediated therapy for cancer. Radiat Res. 2001;155(5):716–23.CrossRefPubMed
57.
Nuyts S, Van Mellaert L, Theys J, Landuyt W, Bosmans E, Anné J, et al. Radio-responsive recA promoter significantly increases TNF [alpha] production in recombinant clostridia after 2 Gy irradiation. Gene Ther. 2001;8(15):1197.CrossRefPubMed
58.
Jiang S-N, Phan TX, Nam T-K, Nguyen VH, Kim H-S, Bom H-S, et al. Inhibition of tumor growth and metastasis by a combination of Escherichia coli–mediated cytolytic therapy and radiotherapy. Mol Ther. 2010;18(3):635–42.CrossRefPubMedPubMedCentral
59.
Platt J, Sodi S, Kelley M, Rockwell S, Bermudes D, Low K, et al. Antitumour effects of genetically engineered Salmonella in combination with radiation. Euro J Cancer. 2000;36(18):2397–402.CrossRef
60.
Liu X, Jiang S, Piao L, Yuan F. Radiotherapy combined with an engineered Salmonella typhimurium inhibits tumor growth in a mouse model of colon cancer. Exp Anim. 2016;65(4):413–8.CrossRefPubMedPubMedCentral
61.
Abdollahi H. Beneficial effects of cellular autofluorescence following ionization radiation: hypothetical approaches for radiation protection and enhancing radiotherapy effectiveness. Med Hypotheses. 2015;84(3):194–8.CrossRefPubMed
62.
Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18(19):3339–45.CrossRefPubMed
63.
Abdollahi H. Probiotic-based protection of normal tissues during radiotherapy. Nutrition. 2014;30(4):495.CrossRefPubMed
64.
Khademi S, Abdollahi H. Application of hydrogen producing microorganisms in radiotherapy: an idea. Iran J Public Health. 2014;43:1018–9.PubMedPubMedCentral
65.
Abdollahi H, Shiri I, Atashzar M, Sarebani M, Moloudi K, Samadian H. Radiation protection and secondary cancer prevention using biological radioprotectors in radiotherapy. Int J Cancer Ther Oncol. 2015;3(3):1–9.
66.
Abdollahi H, Atashzar M, Amini M. The potential use of biogas producing microorganisms in radiation protection. J Med Hypotheses Ideas. 2015;9(2):67–71.CrossRef
67.
Group JFWW, Group JFWW. Guidelines for the evaluation of probiotics in food. London: World Health Organization, ON, Canada: Food and Agriculture Organization. 2002.
68.
Ciorba MA, Riehl TE, Rao MS, Moon C, Ee X, Nava GM, et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut. 2012;61(6):829–38.CrossRefPubMed
69.
Demirer S, Aydıntug S, Aslım B, Kepenekci I, Sengül N, Evirgen O, et al. Effects of probiotics on radiation-induced intestinal injury in rats. Nutrition. 2006;22(2):179–86.CrossRefPubMed
70.
Seal M, Naito Y, Barreto R, Lorenzetti A, Safran P, Marotta F. Experimental radiotherapy-induced enteritis: a probiotic interventional study. J Dig Dis. 2007;8(3):143–7.CrossRefPubMed
71.
Mego M, Holec V, Drgona L, Hainova K, Ciernikova S, Zajac V. Probiotic bacteria in cancer patients undergoing chemotherapy and radiation therapy. Complement Ther Med. 2013;21(6):712–23.CrossRefPubMed
72.
Delia P, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C, et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol. 2007;13(6):912.CrossRefPubMedPubMedCentral
73.
Sharma A, Rath G, Chaudhary S, Thakar A, Mohanti BK, Bahadur S. Lactobacillus brevis CD2 lozenges reduce radiation-and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study. Eur J Cancer. 2012;48(6):875–81.CrossRefPubMed
74.
Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin Nutr. 2014;33(5):761–7.CrossRefPubMed
75.
Österlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007;97(8):1028–34.CrossRefPubMedPubMedCentral
76.
Giralt J, Regadera JP, Verges R, Romero J, de la Fuente I, Biete A, et al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys. 2008;71(4):1213–9.CrossRefPubMed
77.
Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S, et al. Prevention of radiation-induced diarrhea with the use of VSL# 3, a new high-potency probiotic preparation. Am J Gastroenterol. 2002;97(8):2150.CrossRefPubMed
78.
79.
80.
81.
Miladi I, Alric C, Dufort S, Mowat P, Dutour A, Mandon C, et al. The in vivo radiosensitizing effect of gold nanoparticles based MRI contrast agents. Small. 2014;10(6):1116–24.CrossRefPubMed
82.
Detappe A, Lux F, Tillement O. Pushing radiation therapy limitations with theranostic nanoparticles. Nanomed. 2016;11(9):997–9.CrossRef
83.
Sancey L, Lux F, Kotb S, Roux S, Dufort S, Bianchi A, et al. The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy. Br J Radiol. 1041;2014(87):20140134.
84.
Park SJ, Park S-H, Cho S, Kim D-M, Lee Y, Ko SY, et al. New paradigm for tumor theranostic methodology using bacteria-based microrobot. Sci Rep. 2013;3:3394.CrossRefPubMedPubMedCentral
85.
Kojima R, Aubel D, Fussenegger M. Toward a world of theranostic medication: programming biological sentinel systems for therapeutic intervention. Adv Drug Deliv Rev. 2016;105:66–76.CrossRefPubMed
86.
Wu HC, Tsao CY, Quan DN, Cheng Y, Servinsky MD, Carter KK, et al. Autonomous bacterial localization and gene expression based on nearby cell receptor density. Mol Syst Biol. 2013;9(1):636.CrossRefPubMedPubMedCentral
87.
Quispe-Tintaya W, Chandra D, Jahangir A, Harris M, Casadevall A, Dadachova E, et al. Nontoxic radioactive Listeriaat is a highly effective therapy against metastatic pancreatic cancer. Proc Nat Acad Sci. 2013;110(21):8668–73.CrossRefPubMedPubMedCentral
88.
Luo C-H, Huang C-T, Su C-H, Yeh C-S. Bacteria-mediated hypoxia-specific delivery of nanoparticles for tumors imaging and therapy. Nano Lett. 2016;16(6):3493–9.CrossRefPubMed
89.
Martel S, Mohammadi M, Felfoul O, Lu Z, Pouponneau P. Flagellated magnetotactic bacteria as controlled MRI-trackable propulsion and steering systems for medical nanorobots operating in the human microvasculature. Int J Robot Res. 2009;28(4):571–82.CrossRef
90.
Zurkiya O, Chan AW, Hu X. MagA is sufficient for producing magnetic nanoparticles in mammalian cells, making it an MRI reporter. Mag Resonan Med. 2008;59(6):1225–31.CrossRef
91.
Pfeifer F. Distribution, formation and regulation of gas vesicles. Nat Rev Microbiol. 2012;10(10):705–15.CrossRefPubMed
92.
93.
Shapiro MG, Goodwill PW, Neogy A, Yin M, Foster FS, Schaffer DV, et al. Biogenic gas nanostructures as ultrasonic molecular reporters. Nat Nanotechnol. 2014;9(4):311–6.CrossRefPubMedPubMedCentral
94.
Ibsen S, Schutt CE, Esener S. Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment. Drug Des Dev Ther. 2013;7:375–88.CrossRef
95.
Kiessling F, Fokong S, Koczera P, Lederle W, Lammers T. Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics. J Nucl Med. 2012;53(3):345–8.CrossRefPubMed
96.
Wang X, Gkanatsas Y, Palasubramaniam J, Hohmann JD, Chen YC, Lim B, et al. Thrombus-targeted theranostic microbubbles: a new technology towards concurrent rapid ultrasound diagnosis and bleeding-free fibrinolytic treatment of thrombosis. Theranostics. 2016;6(5):726.CrossRefPubMedPubMedCentral
97.
Jibu T, Ando K, Matsumoto T, Koike S, Kobori O, Morioka Y, et al. Active components of intestinal bacteria for abdominal irradiation-induced inhibition of lung metastases. Clin Exp Metastasis. 1991;9(6):529–40.CrossRefPubMed
98.
Fang J, Liao L, Yin H, Nakamura H, Shin T, Maeda H. Enhanced bacterial tumor delivery by modulating the EPR effect and therapeutic potential of Lactobacillus casei. J Pharm Sci. 2014;103(10):3235–43.CrossRefPubMed
99.
Dietzel F, Gericke D, König W. Tumor hyperthermia using high frequency for increase of oncolysis by Clostridium butyricum (M 55). Strahlentherapie. 1976;152(6):537–41.PubMed
100.
Dietzel F, Gericke D. Intensification of the oncolysis by clostridia by means of radio-frequency hyperthermy in experiments on animals–dependence on dosage and on intervals (author’s transl). Strahlentherapie. 1977;153(4):263–6.PubMed
101.
102.
Kainthola A, Gupta N, Agrawala PK. Gastrointestinal microflora in radiation injury and countermeasure. Ann Res Rev Biol. 2016;10(1):1–22.
103.
Liu Q, Nobaek S, Adawi D, Mao Y, Wang M, Molin G, et al. Administration of Lactobacillus plantarum 299v reduces side‐effects of external radiation on colon anastomotic healing in an experimental model. Colorectal Dis. 2001;3(4):245–52.
104.
Chitapanarux I, Chitapanarux T, Traisathit P, Kudumpee S, Tharavichitkul E, Lorvidhaya V. Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol. 2010;5(1):31.
105.
Tanaka I, Tanaka M, Satoh A, Kurematsu A, Ishiwata A, Suzuki K, et al. Alteration of radioprotective effects of heat-killed Lactobacillus casei in X-irradiated C3H/He mouse related to blood level of proinflammatory cytokines by corticoids. J Radiat Res. 2010;51(1):81–6.
106.
García-Peris P, Gimeno CV, Lozano M, Moreno Y, Paron L, de la Cuerda Compés C, et al. Effect of a mixture of inulin and fructo-oligosaccharide on lactobacillus and bifidobacterium intestinal microbiota of patients receiving radiotherapy; a randomised, double-blind, placebo-controlled trial. Nutr Hosp. 2012;27(6):1908–15.
107.
Ki Y, Kim W, Cho H, Ahn K, Choi Y, Kim D. The effect of probiotics for preventing radiation-induced morphological changes in intestinal mucosa of rats. J Korean Med Sci. 2014;29(10):1372–8.
108.
Nomoto K, Yokokura T, Tsuneoka K, Shikita M. Radioprotection of mice by a single subcutaneous injection of heat-killed Lactobacillus casei after irradiation. Radiation Res. 1991;125(3):293–7.
Metadata
Title
The potential roles of bacteria to improve radiation treatment outcome
Authors
E. Kouhsari
A. Ghadimi-Daresajini
H. Abdollahi
N. Amirmozafari
S. R. Mahdavi
S. Abbasian
S. H. Mousavi
H. F. Yaseri
M. Moghaderi
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 2/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1701-7

Other articles of this Issue 2/2018

Clinical and Translational Oncology 2/2018 Go to the issue

Research Article

Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database

Brief Research Article

Histopathological factors predicting response to neoadjuvant therapy in gastric carcinoma

Research Article

Cancer survival in adult patients in Spain. Results from nine population-based cancer registries

Review Article

Key points to optimizing management and research on cancer-associated thrombosis

Research Article

An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis

Research Article

Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits